Fate Therapeutics Inc (FATE)
3.80
-0.07
(-1.81%)
USD |
NASDAQ |
Apr 26, 16:00
3.795
0.00 (0.00%)
Pre-Market: 20:00
Fate Therapeutics Cash from Operations (Quarterly): -36.64M for Dec. 31, 2023
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -36.64M |
| September 30, 2023 | -38.27M |
| June 30, 2023 | -28.49M |
| March 31, 2023 | -28.86M |
| December 31, 2022 | -75.39M |
| September 30, 2022 | -55.05M |
| June 30, 2022 | -53.16M |
| March 31, 2022 | -64.61M |
| December 31, 2021 | -70.29M |
| September 30, 2021 | -33.38M |
| June 30, 2021 | -32.11M |
| March 31, 2021 | -27.10M |
| December 31, 2020 | -20.66M |
| September 30, 2020 | -30.73M |
| June 30, 2020 | 38.84M |
| March 31, 2020 | -26.67M |
| December 31, 2019 | -25.54M |
| September 30, 2019 | -19.84M |
| June 30, 2019 | -20.31M |
| March 31, 2019 | -17.49M |
| December 31, 2018 | -11.02M |
| September 30, 2018 | -3.556M |
| Date | Value |
|---|---|
| June 30, 2018 | -11.52M |
| March 31, 2018 | -12.55M |
| December 31, 2017 | -10.72M |
| September 30, 2017 | -9.769M |
| June 30, 2017 | -8.872M |
| March 31, 2017 | -7.455M |
| December 31, 2016 | -7.551M |
| September 30, 2016 | -7.516M |
| June 30, 2016 | -7.504M |
| March 31, 2016 | -7.252M |
| December 31, 2015 | -6.97M |
| September 30, 2015 | -7.131M |
| June 30, 2015 | 2.079M |
| March 31, 2015 | -6.375M |
| December 31, 2014 | -6.154M |
| September 30, 2014 | -5.521M |
| June 30, 2014 | -5.489M |
| March 31, 2014 | -5.255M |
| December 31, 2013 | -4.578M |
| September 30, 2013 | -3.472M |
| June 30, 2013 | -3.39M |
| March 31, 2013 | -3.933M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-75.39M
Minimum
Dec 2022
38.84M
Maximum
Jun 2020
-34.12M
Average
-30.73M
Median
Sep 2020
Cash from Operations (Quarterly) Benchmarks
| Amicus Therapeutics Inc | 3.458M |
| Regeneron Pharmaceuticals Inc | 1.090B |
| Sarepta Therapeutics Inc | -54.66M |
| ADMA Biologics Inc | 17.60M |
| Ocular Therapeutix Inc | -22.45M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 45.35M |
| Cash from Financing (Quarterly) | -0.18M |
| Free Cash Flow | -138.42M |
| Free Cash Flow Per Share (Quarterly) | -0.3733 |
| Free Cash Flow to Equity (Quarterly) | -36.82M |
| Free Cash Flow Yield | -37.01% |